Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Other Indications, Diabetes |
| Therapuetic Areas: | Endocrinology, Oncology, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/11/2018 |
| Start Date: | August 7, 2018 |
| End Date: | August 2021 |
| Contact: | Cemre Robinson, MD |
| Email: | cemre.robinson@yale.edu |
| Phone: | (203) 737-3784 |
The investigators' objective is to understand the pathogenesis of diabetes mellitus in
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of
insulin resistance versus impaired insulin secretion, 2) investigating presence of excess
glucagon signaling by measuring gluconeogenesis and glycogenolysis, and 3) investigating a
potential interaction between diabetes and intraductal papillary mucinous neoplasms (IPMNs).
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of
insulin resistance versus impaired insulin secretion, 2) investigating presence of excess
glucagon signaling by measuring gluconeogenesis and glycogenolysis, and 3) investigating a
potential interaction between diabetes and intraductal papillary mucinous neoplasms (IPMNs).
Specific project aims include:
Aim 1: Determine insulin secretion and sensitivity in subjects with MAS-associated diabetes.
Aim 2: Measure gluconeogenesis and glycogenolysis in MAS-associated diabetes to investigate a
potential role for excess glucagon signaling.
Aim 3: Determine if IPMN development is associated with impairment of insulin secretion prior
to development of overt diabetes.
The authors expect that this study will:
1. Establish the etiology of diabetes in FD/MAS
2. Increase understanding of the role of IPMNs in pathogenesis of diabetes
3. Provide critical insights into the pathogenesis of diabetes in FD/MAS
Aim 1: Determine insulin secretion and sensitivity in subjects with MAS-associated diabetes.
Aim 2: Measure gluconeogenesis and glycogenolysis in MAS-associated diabetes to investigate a
potential role for excess glucagon signaling.
Aim 3: Determine if IPMN development is associated with impairment of insulin secretion prior
to development of overt diabetes.
The authors expect that this study will:
1. Establish the etiology of diabetes in FD/MAS
2. Increase understanding of the role of IPMNs in pathogenesis of diabetes
3. Provide critical insights into the pathogenesis of diabetes in FD/MAS
Inclusion Criteria:
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) group:
- Must be diagnosed based on clinical grounds and/or mutation testing on bone and/or
affected tissue
Control group:
- Must be at least 18 years old
Exclusion Criteria:
Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) group:
- Unwilling to fully cooperate with the evaluation
- Unable to provide informed consent
Control group:
- History of diabetes, insulin resistance, pancreatic disease, pancreatic cysts or
amylase/lipase abnormality
- Use of any type of oral diabetes medications and/or insulin
- Unable to provide informed consent
We found this trial at
1
site
20 York St, N20 York St,
New Haven, Connecticut 06520
New Haven, Connecticut 06520
(203) 688-4242
Phone: 203-785-5809
Yale-New Haven Hospital Relying on the skill and expertise of more than 4,500 university and...
Click here to add this to my saved trials
